Cargando…

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells

Non-small cell lung cancer (NSCLC) is often characterized by an underlying mutation in the epidermal growth factor receptor (EGFR), contributing to aggressive metastatic disease. Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me), a glycyrrhetinic acid derivative, reportedly improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nottingham, Ebony, Mazzio, Elizabeth, Surapaneni, Sunil Kumar, Kutlehria, Shallu, Mondal, Arindam, Badisa, Ramesh, Safe, Stephen, Rishi, Arun K., Singh, Mandip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Xi'an Jiaotong University 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740161/ https://www.ncbi.nlm.nih.gov/pubmed/35028186 http://dx.doi.org/10.1016/j.jpha.2021.06.002

Ejemplares similares

Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening
por: Gebeyehu, Aragaw, et al.
Publicado: (2021)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Erlotinib-induced dry eye
por: Ravisankar, Rashmita, et al.
Publicado: (2023)

Propargylaminyl 3α-hydroxy-11-oxo-18β-olean-12-en-29-oate
por: Czollner, Laszlo, et al.
Publicado: (2011)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Cutaneous Leukocytoclastic Vasculitis Associated with Erlotinib
por: Sawada, Takahiro, et al.
Publicado: (2016)

Toxicité cutanée à l'erlotinib
por: Bourra, Hayat, et al.
Publicado: (2013)

Stability and Formulation of Erlotinib in Skin Creams
por: Nguyen, David, et al.
Publicado: (2022)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

A Case of Cicatricial Alopecia Associated with Erlotinib
por: Yang, Bo Hee, et al.
Publicado: (2011)

Erlotinib hydrochloride: an anticancer agent
por: Selvanayagam, S., et al.
Publicado: (2008)

Acute Fatal Liver Toxicity under Erlotinib
por: Schacher-Kaufmann, Sabina, et al.
Publicado: (2010)

Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma
por: ZHANG, HUAN-HUAN, et al.
Publicado: (2013)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Trichomegaly of Eyelashes after Treatment with Erlotinib in Carcinoma Pancreas
por: Goel, Varun, et al.
Publicado: (2014)

Metformin and erlotinib synergize to inhibit basal breast cancer
por: Lau, Ying-Ka Ingar, et al.
Publicado: (2014)

Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
por: Kim, En Hyung, et al.
Publicado: (2022)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
por: Tang, Joy, et al.
Publicado: (2013)

Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft
por: Siu, I-Mei, et al.
Publicado: (2013)

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
por: Hirte, Hal W
Publicado: (2013)

Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Oncogenic miR-9 is a target of erlotinib in NSCLCs
por: Chen, Xi, et al.
Publicado: (2015)

Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases
por: Read, William L., et al.
Publicado: (2015)

Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
por: Akoglu, Gulsen, et al.
Publicado: (2016)

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
por: Cardin, Dana B, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qfa6a0gf4pulmhlqghqkk9jtl6